Premier Anti-Aging Co., Ltd. (4934) AI Stock Analysis

• Market Cap: ¥6.99B
• Dividend Yield: N/A
• Average Volume (3M): 28.04K
• Price to Earnings (P/E): 14.8
• Beta (1Y): 1.03
• Revenue Growth: -20.62%
• EPS Growth: N/A
• Country: JP
• Employees: 229
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): -33.39
• Shares Outstanding: 8,720,534
• 10 Day Avg. Volume: 41,510
• 30 Day Avg. Volume: 28,043
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥914.00
• Price Target Upside: 14.11% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 56 Neutral
• Price Target: ¥914.00 ▲(14.11% Upside)

The overall stock score reflects financial challenges, particularly declining revenues and cash flow issues, which are the most significant factors. Technical analysis indicates a lack of strong momentum, and while the valuation is reasonable, the absence of a dividend yield is a drawback.

Premier Anti-Aging Co., Ltd. Business Overview & Revenue Model

Company Description

Premier Anti-Aging Co., Ltd. (4934) is a Japanese company specializing in the development and sale of skincare and beauty products, primarily focused on anti-aging solutions. The company operates in the personal care sector, offering a range of products that target aging concerns, leveraging advanced technologies and ingredients to cater to the needs of consumers seeking youthful and radiant skin.

How the Company Makes Money

Premier Anti-Aging Co., Ltd. generates revenue through the direct sale of its skincare and beauty products. The company's primary revenue streams include online sales via its e-commerce platforms and physical sales through retail partners. Premier Anti-Aging Co., Ltd. benefits from a strong brand presence and effective marketing strategies, which help in capturing a significant share of the anti-aging market. Strategic partnerships and collaborations with retailers and distributors also play a crucial role in expanding its reach and driving sales. Additionally, the company invests in research and development to continuously innovate and enhance its product offerings, ensuring customer satisfaction and loyalty.

Premier Anti-Aging Co., Ltd. Financial Statement Overview

Summary

The company is experiencing financial challenges with declining revenues and profitability. While the balance sheet is stable, cash flow issues and negative net profit margins are concerning. Improvement in revenue growth and cash flow management is necessary.

Income Statement

The income statement reveals a concerning trend of declining revenue and profitability. The gross profit margin has remained high, but net profit margin has been negative for recent years, with 2024 showing significant net losses. Revenue has decreased consistently since 2022, indicating problematic revenue growth and operational challenges.

Balance Sheet

The balance sheet is relatively stable, with a steady stockholders' equity and manageable debt levels. The debt-to-equity ratio remains reasonable, and the equity ratio is healthy, indicating a solid capital structure. However, declining total assets could pose a risk if the trend continues.

Cash Flow

Cash flow analysis shows fluctuating free cash flow, with recent periods experiencing negative figures. Operating cash flow has been positive, but the lack of consistent free cash flow growth is a concern. The company needs to improve cash flow management to ensure financial stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.24B	20.36B	26.40B	33.91B	32.81B	20.51B
Gross Profit	14.39B	16.10B	19.24B	26.63B	26.43B	16.48B
EBITDA	1.47B	-627.00M	-432.24M	2.67B	4.71B	1.68B
Net Income	783.00M	-1.48B	-733.97M	1.42B	2.79B	1.14B
Balance Sheet
Total Assets	10.96B	11.00B	12.14B	12.30B	13.07B	6.85B
Cash, Cash Equivalents and Short-Term Investments	5.31B	4.76B	4.67B	2.97B	6.06B	1.90B
Total Debt	1.78B	2.44B	2.26B	1.41B	911.41M	1.99B
Total Liabilities	4.25B	4.88B	4.53B	3.95B	6.17B	5.40B
Stockholders Equity	6.71B	6.12B	7.61B	8.35B	6.90B	1.45B
Cash Flow
Free Cash Flow	0.00	-395.00M	1.64B	-3.53B	2.68B	196.34M
Operating Cash Flow	0.00	425.00M	2.42B	-3.32B	2.75B	338.23M
Investing Cash Flow	0.00	-540.00M	-900.97M	-297.68M	-180.83M	-135.76M
Financing Cash Flow	0.00	183.00M	179.77M	501.62M	1.58B	979.68M

Premier Anti-Aging Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 801.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4934, the sentiment is Negative. The current price of 801 is below the 20-day moving average (MA) of 868.95, below the 50-day MA of 880.40, and below the 200-day MA of 851.32, indicating a bearish trend. The MACD of -22.22 indicates Positive momentum. The RSI at 29.36 is Positive, neither overbought nor oversold. The STOCH value of 0.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4934.

Premier Anti-Aging Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4936	65 Neutral	11.21B	30.51	―	2.15%	10.56%	-52.16%
4925	63 Neutral	6.80B	10.54	6.46%	2.22%	-3.27%	―
4929	62 Neutral	6.20B	160.59	0.97%	1.55%	-9.81%	―
4934	56 Neutral	¥6.99B	14.83	―	―	-20.62%	―
4935	53 Neutral	12.79B	-78.76	-1.35%	0.43%	9.74%	-669.35%
4926	45 Neutral	5.18B	20.47	―	1.65%	7.21%	―
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%

Premier Anti-Aging Co., Ltd. Corporate Events

Premier Anti-Aging Revises Earnings Forecast Amid Mixed Business Performance

Premier Anti-Aging Co., Ltd. has revised its full-year consolidated earnings forecast for the fiscal year ending July 31, 2025, due to mixed performance across its business segments. While the recovery business through subsidiary Venex Co., Ltd. showed strong sales, the anti-aging segment underperformed, leading to an overall reduction in expected net sales. Despite this, operating profit exceeded expectations due to reduced advertising expenses and effective cost management. The company plans to invest in marketing for its renewed ‘DUO’ brand and new ‘Lalaskin’ skincare line, while remaining cautious about the challenging business environment, particularly in the Chinese market.

Premier Anti-Aging Reports Financial Results and Revises Forecasts

Premier Anti-Aging Co., Ltd. reported a decrease in net sales and operating profits for the first nine months of the fiscal year ending July 31, 2025, compared to the previous year. Despite the decline in sales, the company achieved a profit attributable to owners of the parent, indicating a recovery from the previous year’s losses. The company has revised its earnings forecasts for the full fiscal year, suggesting a cautious yet optimistic outlook for future performance.